Aggregated price index with volume information
Summary:
- Pharmaceuticals: Generic stocks up 3.1% on average while median return up 1.5% in a day
- Pharmaceuticals: Generic stocks up 4.5% on average while median return up 3.3% in a week
- Pharmaceuticals: Generic stocks up 8.9% on average while median return up 12.8% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $LFVN 21.7%, $SMTI 16.7%, $BBIO 14.8%
- 1M losers are : Losers for past month are
- 1W winners are : Winners for past week are $LFVN 21.3%, $SMTI 8.4%, $RDY 4.0%
- 1W losers are : Losers for past week are $TXMD -0.5%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 8.3%, for the past 3 months is 3.6%
In the past month for a 5 days rolling window, the highest corrrelation is 29.8%, the lowest correlation is -9.2%, the latest correlation is 1.4%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 65.1% between BBIO and SMTI
The lowest correlation is -35.7% between COCP and ZTS
Key Insights Using the 2 Stage Free Cash Flow to Equity, Zoetis fair value estimate is US$205 Current share price of...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr.
Calls will highlight how company is ahead of industry with recent transformation initiatives, innovative compensation plan, award-winning, activating products, and vibrant entrepreneurial communitySALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVan
Reaffirms commitment to direct selling industry and its vibrant communitySALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, held its global Activate 2024 virtual event on Saturday, July 20, 2024. The event, supported by Consultant-hosted watch parties and local gatherings, served as a platform to reaffirm its commitment to the direct sell
By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update No Safety or Tolerability Issues for CDI-988 in SAD Cohorts On July 18, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 trial of CDI-988, the company’s broad-spectrum antiviral inhibitor of 3CL viral proteases.
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers with CDI-988, its potent, oral, pan-viral protease inhibitor. CDI-988 was specifically designed and developed using Cocrystal’s proprietary structure-based drug discovery platform technology as a broad-spectrum antiviral inhibitor to a
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
LifeVantage (NASDAQ:LFVN) has had a rough month with its share price down 12%. However, the company's fundamentals look...
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
One key principle of long-term investing is letting your winners run. Charlies Munger reiterated this idea in his famous maxim; “The first rule of compounding: Never interrupt it unnecessarily.” This approach works with long-term stocks, especially those with durable competitive advantages. The following long-term stocks are well-positioned to deliver attractive shareholder returns for decades. First, they are on a solid financial footing with robust balance sheets. This stability is essential,